Error in Tables in: A Randomized, Placebo-Controlled Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8 and A Randomized, Placebo-Controlled Clinical Trial of High-Dose Supplementation With Vitamins C and E and Beta Carotene for Age-Related Cataract and Vision Loss

2008 ◽  
Vol 126 (9) ◽  
pp. 1251 ◽  
Keyword(s):  
Clinical Trial ◽  
Macular Degeneration ◽  
Vision Loss ◽  
Beta Carotene ◽  
Age Related Macular Degeneration ◽  
Controlled Clinical Trial ◽  
High Dose ◽  
Age Related

Does High-Dose Supplementation with Vitamins C and E, Beta Carotene, and Zinc Slow the Progression of Age-Related Macular Degeneration and Vision Loss?

2020 ◽  
pp. 219-224
Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins
Keyword(s):  
Macular Degeneration ◽  
Vision Loss ◽  
Beta Carotene ◽  
Geographic Atrophy ◽  
Age Related Macular Degeneration ◽  
High Dose ◽  
Age Related ◽  
Intermediate Size ◽  
Zinc Supplements ◽  
Disease Study

The Age-Related Eye Disease Study (AREDS) was a randomized, double-masked, clinical trial with two components, an age-related macular degeneration (AMD) trial and a cataract trial. This paper reports the results of the AMD trial, which was designed to determine the effect of high-dose vitamins C and E, beta carotene, and zinc supplements on the progression of AMD and vision loss. Based on the study findings, the authors recommended that individuals fifty-five years of age and older with extensive intermediate size drusen, at least one large druse, noncentral geographic atrophy in one or both eyes, or advanced AMD or vision loss due to AMD in one eye, and without contraindications such as smoking, should consider taking a supplement of antioxidants (consisting of vitamin C and E and beta carotene) plus zinc.

scholarly journals Microvascular abnormalities secondary to radiation therapy in neovascular age-related macular degeneration: findings from the INTREPID clinical trial

2018 ◽  
Vol 103 (4) ◽  
pp. 469-474 ◽  
Author(s):  
Florentina Joyce Freiberg ◽  
Stephan Michels ◽  
Alyson Muldrew ◽  
Jason Slakter ◽  
Denis O’Shaughnessy ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Macular Degeneration ◽  
Vision Loss ◽  
Visual Outcome ◽  
Retinal Vessel ◽  
Age Related Macular Degeneration ◽  
Controlled Clinical Trial ◽  
Anti Vegf ◽  
Age Related ◽  
Endothelial Growth Factor

PurposeTo report the incidence and features of retinal microvascular abnormalities (MVAs) occurring secondary to stereotactic radiotherapy (SRT) in a randomised double-masked sham-controlled clinical trial at 21 European sites.MethodsTwo hundred and thirty participants with neovascular age-related macular degeneration (AMD) treated with at least three intravitreal antivascular endothelial growth factor (anti-VEGF) injections prior to enrolment, and demonstrating a continuing need for re-treatment. Interventions: 16 Gy, 24 Gy or sham SRT. All three groups received pro re nata anti-VEGF injections if the lesion was judged to be active at review visits. Colour fundus images from baseline and 6 months and fluorescein angiograms from baseline and annual visits were graded for measures of morphological outcome and safety using a prespecified protocol with accompanying definitions to distinguish RT-related MVA from non-specific retinal vessel abnormalities that are known to occur in neovascular AMD. The main outcome measure was MVA detected by months 12, 24 and 36 after enrolment.ResultsThe frequency of MVAs in the combined SRT arms was 0% in year 1, 13.1% in year 2 and 30.3% in year 3. The area of MVA was small and the mean change in visual acuity in year 2 was similar in a subset of SRT eyes with MVAs, versus those without MVAs. MVA was considered to have possibly contributed to vision loss in 2 of 18 cases with MVA in year 2, and 5 of 37 cases in year 3.ConclusionTreatment with SRT is associated with development of subtle MVAs that have little or no impact on visual outcome. These findings can help clinicians recognise the retinal MVAs that occur in response to SRT.

Proton therapy for exudative age-related macular degeneration: a randomized, sham-controlled clinical trial

2002 ◽  
Vol 134 (6) ◽  
pp. 905-906 ◽  
Author(s):  
Thomas A Ciulla ◽  
Ronald P Danis ◽  
Susan B Klein ◽  
Victor E Malinovsky ◽  
P.Sarita Soni ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Macular Degeneration ◽  
Proton Therapy ◽  
Age Related Macular Degeneration ◽  
Controlled Clinical Trial ◽  
Age Related

Ranibizumab for Neovascular Age-Related Macular Degeneration

2020 ◽  
pp. 245-250
Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Choroidal Neovascularization ◽  
Vision Loss ◽  
Age Related Macular Degeneration ◽  
Controlled Clinical Trial ◽  
Serious Adverse Events ◽  
Double Blind ◽  
Age Related ◽  
Endothelial Growth Factor

The Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) study was a randomized, double-blind, sham-controlled clinical trial to determine whether intravitreal administration of ranibizumab (an anti-vascular endothelial growth factor [VEGF] agent) prevents vision loss and improves mean visual acuity in patients with minimally classic or occult choroidal neovascularization related to age-related macular degeneration (AMD). Ranibizumab therapy was associated with clinically and statistically significant benefits in visual acuity and the amount of angiographic leakage from choroidal neovascularization during two years of follow-up, with low rates of serious adverse events.

Sign in / Sign up

Export Citation Format

Share Document